Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
WallStreetSelect 114
WallStreetSelect 114
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Vaxcyte Inc
(NQ:
PCVX
)
109.15
-1.00 (-0.91%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Sep 4, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Vaxcyte Inc
< Previous
1
2
Next >
MarketBeat Week in Review – 4/17 - 4/21
April 22, 2023
Markets ended the week on a down note as further evidence that the markets are likely to continue to bounce around but could get a jolt from earnings next week
Via
MarketBeat
Topics
Economy
Exposures
Interest Rates
Vaxcyte Announces Closing of $575 Million Public Offering Including Full Exercise of Underwriters’ Option to Purchase Additional Shares
April 21, 2023
From
Vaxcyte, Inc.
Via
GlobeNewswire
Vaxcyte Announces Pricing of $500 Million Public Offering
April 19, 2023
From
Vaxcyte, Inc.
Via
GlobeNewswire
Still 50% Upside To Go, Wall Street Is Getting Vaxcyte Right
April 18, 2023
When a biotech company delivers chart-busting news, more often follows. In a space that can be like throwing darts, Wall Street has bullseyes on Vaxcyte, Inc.
Via
MarketBeat
Vaxcyte Announces Commencement of Proposed Public Offering of Common Stock and Pre-Funded Warrants
April 17, 2023
From
Vaxcyte, Inc.
Via
GlobeNewswire
Vaxcyte Reports Positive Data from Phase 2 Study of its 24-Valent Pneumococcal Conjugate Vaccine Candidate, VAX-24, in Adults Aged 65 and Older and Full Six-Month Safety Data from Adult Phase 1/2 and Phase 2 Studies
April 17, 2023
From
Vaxcyte, Inc.
Via
GlobeNewswire
Vaxcyte to Host Webcast and Conference Call to Discuss Results from Phase 2 Study of its 24-Valent Pneumococcal Conjugate Vaccine Candidate in Adults Aged 65 and Older and Full Six-Month Safety Data from Both Adult Phase 2 Studies
April 16, 2023
From
Vaxcyte, Inc.
Via
GlobeNewswire
Vaxcyte Doses First Participants in Phase 2 Study Evaluating VAX-24 for the Prevention of Invasive Pneumococcal Disease in Infants
March 30, 2023
From
Vaxcyte, Inc.
Via
GlobeNewswire
Vaxcyte Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update
February 27, 2023
From
Vaxcyte, Inc.
Via
GlobeNewswire
Vaxcyte Announces FDA Clearance of Investigational New Drug Application for VAX-24 for the Prevention of Invasive Pneumococcal Disease in Infants
February 21, 2023
From
Vaxcyte, Inc.
Via
GlobeNewswire
Vaxcyte to Report Fourth Quarter and Full Year 2022 Financial Results on February 27, 2023
February 16, 2023
From
Vaxcyte, Inc.
Via
GlobeNewswire
Vaxcyte to Present at the SVB Securities Global Biopharma Conference
February 07, 2023
From
Vaxcyte, Inc.
Via
GlobeNewswire
Vaxcyte’s VAX-24 Granted FDA Breakthrough Therapy Designation for the Prevention of Invasive Pneumococcal Disease in Adults
January 05, 2023
From
Vaxcyte, Inc.
Via
GlobeNewswire
Vaxcyte Reports Third Quarter 2022 Financial Results and Provides Business Update
November 07, 2022
From
Vaxcyte, Inc.
Via
GlobeNewswire
Vaxcyte to Present at Upcoming Investor Conferences
November 03, 2022
From
Vaxcyte, Inc.
Via
GlobeNewswire
Why Investors Are Suddenly Excited About Vaxcyte
October 31, 2022
Vaxcyte, Inc. is a small cap biotech company that catapulted back to mid-cap land with a stunning 110% surge — and may not be done yet.
Via
MarketBeat
Exposures
COVID-19
Vaxcyte Announces Closing of $690 Million Public Offering Including Full Exercise of Underwriters’ Option to Purchase Additional Shares
October 28, 2022
From
Vaxcyte, Inc.
Via
GlobeNewswire
Vaxcyte Announces Pricing of $600 Million Public Offering
October 26, 2022
From
Vaxcyte, Inc.
Via
GlobeNewswire
Vaxcyte Announces Commencement of Proposed Public Offering of Common Stock and Pre-Funded Warrants
October 24, 2022
From
Vaxcyte, Inc.
Via
GlobeNewswire
Vaxcyte Reports Positive Topline Data from Phase 1/2 Proof-of-Concept Study of its 24-Valent Pneumococcal Conjugate Vaccine Candidate Being Investigated for the Prevention of Invasive Pneumococcal Disease in Adults Aged 18-64
October 24, 2022
From
Vaxcyte, Inc.
Via
GlobeNewswire
Vaxcyte to Host Webcast and Conference Call to Discuss Topline Results from the Phase 1/2 Proof-of-Concept Study of VAX-24 Being Investigated for the Prevention of Invasive Pneumococcal Disease in Adults
October 23, 2022
From
Vaxcyte, Inc.
Via
GlobeNewswire
Vaxcyte Expands Executive Leadership Team with Key Appointments
October 11, 2022
From
Vaxcyte, Inc.
Via
GlobeNewswire
< Previous
1
2
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.